OP61 – 2294: Pantotenate kinase associated neurodegeneration: Clinical assessment and genetic characterization by means of a Spanish multi-centre research network
We aimed to design and validate a quantitative method for clinical assessment of pantothenate kinase associated neurodegeneration (PKAN). Cross-sectional multicenter study of PKAN patients recruited through professional associations. Design of a Disease Rating Scale for PKAN (PKAN-DRS) including fiv...
Gespeichert in:
| Veröffentlicht in: | European journal of paediatric neurology Jg. 19; S. S19 - S20 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Elsevier Ltd
01.05.2015
|
| Schlagworte: | |
| ISSN: | 1090-3798 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | We aimed to design and validate a quantitative method for clinical assessment of pantothenate kinase associated neurodegeneration (PKAN).
Cross-sectional multicenter study of PKAN patients recruited through professional associations. Design of a Disease Rating Scale for PKAN (PKAN-DRS) including five sub-scales: cognitive, behavioral, dystonia, parkinsonism, other neurological signs and disability. Items were scored from 0 to 3–4 (maximum severity), (total scores 0–125). For validity and reliability assessment, three independent examiners rated PKAN patients using recorded videotapes. Sanger sequencing of NBIA genes was performed in unsolved NBIA families.
13 PKAN patients (mean age 32 years, range 8–77) were assessed through the PKAN-DRS (scores 29–71). Higher scores were obtained in the following items: postural instability, bradikinesia and freezing (parkinson subscale); jaw-tongue, lower face, foot and hand (dystonia subscale); gait and speech (other neurologic signs). Spearman correlation tests showed significant positive correlations between disability and physical scores. Age at diagnosis correlated negatively with dystonia and positively with Parkinsonism. Parkinsonism and disability increased significantly with disease duration. The ICCs for inter-observer agreement was considered “almost perfect” (ICC=0.97), with an internal reliability when all subscales are included considered as “good” (Cronbach's alpha = 0.85). Regarding inter-item evaluation, reliability was considered “good” for dystonia, parkinsonism and disability sub-scores (0.87, 0.82 and 0.88, respectively) and “poor” for other neurological signs (0.20). Six homozygous p. T528M gipsy patients obtained lower PKAN-DRS scores for all subscales when compared with the group of patients with other mutations.
The proposed PKAN-DRS seems a reliable method to assess the more prevalent neurologic signs in PKAN. Dystonia was more severe in patients with an earlier disease onset, predominating in the jaw and tongue and in the distal limbs. Atypical parkinsonism worsened with disease duration. Haplotype studies are necessary to search for a possible founder effect of the mutation p. T528M in our population. |
|---|---|
| AbstractList | We aimed to design and validate a quantitative method for clinical assessment of pantothenate kinase associated neurodegeneration (PKAN).
Cross-sectional multicenter study of PKAN patients recruited through professional associations. Design of a Disease Rating Scale for PKAN (PKAN-DRS) including five sub-scales: cognitive, behavioral, dystonia, parkinsonism, other neurological signs and disability. Items were scored from 0 to 3–4 (maximum severity), (total scores 0–125). For validity and reliability assessment, three independent examiners rated PKAN patients using recorded videotapes. Sanger sequencing of NBIA genes was performed in unsolved NBIA families.
13 PKAN patients (mean age 32 years, range 8–77) were assessed through the PKAN-DRS (scores 29–71). Higher scores were obtained in the following items: postural instability, bradikinesia and freezing (parkinson subscale); jaw-tongue, lower face, foot and hand (dystonia subscale); gait and speech (other neurologic signs). Spearman correlation tests showed significant positive correlations between disability and physical scores. Age at diagnosis correlated negatively with dystonia and positively with Parkinsonism. Parkinsonism and disability increased significantly with disease duration. The ICCs for inter-observer agreement was considered “almost perfect” (ICC=0.97), with an internal reliability when all subscales are included considered as “good” (Cronbach's alpha = 0.85). Regarding inter-item evaluation, reliability was considered “good” for dystonia, parkinsonism and disability sub-scores (0.87, 0.82 and 0.88, respectively) and “poor” for other neurological signs (0.20). Six homozygous p. T528M gipsy patients obtained lower PKAN-DRS scores for all subscales when compared with the group of patients with other mutations.
The proposed PKAN-DRS seems a reliable method to assess the more prevalent neurologic signs in PKAN. Dystonia was more severe in patients with an earlier disease onset, predominating in the jaw and tongue and in the distal limbs. Atypical parkinsonism worsened with disease duration. Haplotype studies are necessary to search for a possible founder effect of the mutation p. T528M in our population. Objective We aimed to design and validate a quantitative method for clinical assessment of pantothenate kinase associated neurodegeneration (PKAN). Methods Cross-sectional multicenter study of PKAN patients recruited through professional associations. Design of a Disease Rating Scale for PKAN (PKAN-DRS) including five sub-scales: cognitive, behavioral, dystonia, parkinsonism, other neurological signs and disability. Items were scored from 0 to 3–4 (maximum severity), (total scores 0–125). For validity and reliability assessment, three independent examiners rated PKAN patients using recorded videotapes. Sanger sequencing of NBIA genes was performed in unsolved NBIA families. Results 13 PKAN patients (mean age 32 years, range 8–77) were assessed through the PKAN-DRS (scores 29–71). Higher scores were obtained in the following items: postural instability, bradikinesia and freezing (parkinson subscale); jaw-tongue, lower face, foot and hand (dystonia subscale); gait and speech (other neurologic signs). Spearman correlation tests showed significant positive correlations between disability and physical scores. Age at diagnosis correlated negatively with dystonia and positively with Parkinsonism. Parkinsonism and disability increased significantly with disease duration. The ICCs for inter-observer agreement was considered “almost perfect” (ICC=0.97), with an internal reliability when all subscales are included considered as “good” (Cronbach's alpha = 0.85). Regarding inter-item evaluation, reliability was considered “good” for dystonia, parkinsonism and disability sub-scores (0.87, 0.82 and 0.88, respectively) and “poor” for other neurological signs (0.20). Six homozygous p. T528M gipsy patients obtained lower PKAN-DRS scores for all subscales when compared with the group of patients with other mutations. Conclusion The proposed PKAN-DRS seems a reliable method to assess the more prevalent neurologic signs in PKAN. Dystonia was more severe in patients with an earlier disease onset, predominating in the jaw and tongue and in the distal limbs. Atypical parkinsonism worsened with disease duration. Haplotype studies are necessary to search for a possible founder effect of the mutation p. T528M in our population. |
| Author | Darling, A. Decio, A. Vila, M.T. Serrano, M. Madruga, M. Pujol, M. Espinós, C. Pérez-Dueñas, B. Vicente, C. Tello Martí, M.J. López, A. Martorell, L. Lupo, V. Albesa, S. Aguilera Zubimendi, I.G. Quadras, D. |
| Author_xml | – sequence: 1 givenname: A. surname: Darling fullname: Darling, A. – sequence: 2 givenname: A. surname: Decio fullname: Decio, A. – sequence: 3 givenname: M. surname: Serrano fullname: Serrano, M. – sequence: 4 givenname: S. Aguilera surname: Albesa fullname: Albesa, S. Aguilera – sequence: 5 givenname: I.G. surname: Zubimendi fullname: Zubimendi, I.G. – sequence: 6 givenname: M.T. surname: Vila fullname: Vila, M.T. – sequence: 7 givenname: M. surname: Madruga fullname: Madruga, M. – sequence: 8 givenname: M. surname: Pujol fullname: Pujol, M. – sequence: 9 givenname: D. surname: Quadras fullname: Quadras, D. – sequence: 10 givenname: C. Tello surname: Vicente fullname: Vicente, C. Tello – sequence: 11 givenname: V. surname: Lupo fullname: Lupo, V. – sequence: 12 givenname: A. surname: López fullname: López, A. – sequence: 13 givenname: L. surname: Martorell fullname: Martorell, L. – sequence: 14 givenname: C. surname: Espinós fullname: Espinós, C. – sequence: 15 givenname: M.J. surname: Martí fullname: Martí, M.J. – sequence: 16 givenname: B. surname: Pérez-Dueñas fullname: Pérez-Dueñas, B. |
| BookMark | eNqNkN9KXDEQh3NhoWr7CEIu68WpmWTPP0FLWawtCArW6zDOmdONu5tIkm3ZXvUd-go-WZ-k5-xKLwSxV0OG-X0z-fbEjg-ehTgA9R4UVEfXoFpVmLpt3kF5aJSqdGF2xO6_9muxl9KdUqqd6GpXPFxeVSD__PottW4nx_IKfQ6ZPWaWc-cxscSUArmh0UnPqxg6_saeI2YX_LGcLpx3hItxjFNass8SfSfHmexI0gwjUubofm4S8nYtl4w-ydBLlNf36F2ayeVqkV1BQzqyjJwYI82GfflHiPM34lWPi8RvH-u-uPl09nX6ubi4PP8y_XhRkAYwxaStW-KWe91NDKmmpbIDIN0Q1Ng00GCDw6synWZTMfItqxrKvuK61ropzb4ot1yKIaXIvb2PbolxbUHZUa_d6LWjRwul3ei1Zsh92OZ4OO6742gTOfbEnYtM2XbBvUg4fUKgR69zXnO6C6voh59bsElbtYWMDCg3hBFw8jzgPw74Cx03sYQ |
| ContentType | Journal Article |
| Copyright | 2015 European Paediatric Neurology Society European Paediatric Neurology Society |
| Copyright_xml | – notice: 2015 European Paediatric Neurology Society – notice: European Paediatric Neurology Society |
| DBID | AAYXX CITATION |
| DOI | 10.1016/S1090-3798(15)30062-3 |
| DatabaseName | CrossRef |
| DatabaseTitle | CrossRef |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EndPage | S20 |
| ExternalDocumentID | 10_1016_S1090_3798_15_30062_3 S1090379815300623 1_s2_0_S1090379815300623 |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 1B1 1P~ 1~. 1~5 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXLA AAXUO AAYWO ABBQC ABCQJ ABFNM ABJNI ABMAC ABMZM ABTEW ABWVN ABXDB ACDAQ ACGFS ACIEU ACLOT ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO AEBSH AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGHFR AGQPQ AGUBO AGWIK AGYEJ AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CAG COF CS3 DU5 EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IHE J1W KOM M41 MO0 MOBAO N9A O-L O9- OAUVE OP~ OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SDF SDG SEL SES SEW SPCBC SSH SSN SSZ T5K Z5R ~G- ~HD AACTN AFCTW AFKWA AJOXV AMFUW RIG 9DU AAYXX CITATION |
| ID | FETCH-LOGICAL-c2113-4979ce9ef2d43c089c5d11c28c17a8818a8ac2863d2e36eaebe0715f6e7722853 |
| ISSN | 1090-3798 |
| IngestDate | Sat Nov 29 01:31:40 EST 2025 Thu Feb 27 05:28:09 EST 2025 Sun Feb 23 10:19:04 EST 2025 Tue Oct 14 19:40:39 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c2113-4979ce9ef2d43c089c5d11c28c17a8818a8ac2863d2e36eaebe0715f6e7722853 |
| ParticipantIDs | crossref_primary_10_1016_S1090_3798_15_30062_3 elsevier_sciencedirect_doi_10_1016_S1090_3798_15_30062_3 elsevier_clinicalkeyesjournals_1_s2_0_S1090379815300623 elsevier_clinicalkey_doi_10_1016_S1090_3798_15_30062_3 |
| PublicationCentury | 2000 |
| PublicationDate | May 2015 |
| PublicationDateYYYYMMDD | 2015-05-01 |
| PublicationDate_xml | – month: 05 year: 2015 text: May 2015 |
| PublicationDecade | 2010 |
| PublicationTitle | European journal of paediatric neurology |
| PublicationYear | 2015 |
| Publisher | Elsevier Ltd |
| Publisher_xml | – name: Elsevier Ltd |
| SSID | ssj0009426 |
| Score | 2.025826 |
| Snippet | We aimed to design and validate a quantitative method for clinical assessment of pantothenate kinase associated neurodegeneration (PKAN).
Cross-sectional... Objective We aimed to design and validate a quantitative method for clinical assessment of pantothenate kinase associated neurodegeneration (PKAN). Methods... |
| SourceID | crossref elsevier |
| SourceType | Index Database Publisher |
| StartPage | S19 |
| SubjectTerms | Neurology Pediatrics |
| Title | OP61 – 2294: Pantotenate kinase associated neurodegeneration: Clinical assessment and genetic characterization by means of a Spanish multi-centre research network |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1090379815300623 https://www.clinicalkey.es/playcontent/1-s2.0-S1090379815300623 https://dx.doi.org/10.1016/S1090-3798(15)30062-3 |
| Volume | 19 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 issn: 1090-3798 databaseCode: AIEXJ dateStart: 19970101 customDbUrl: isFulltext: true dateEnd: 99991231 titleUrlDefault: https://www.sciencedirect.com omitProxy: false ssIdentifier: ssj0009426 providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3LbtNAFB2FFCE2iKcoL80CJJDl4hk_p7uoFAGiJVKKlN1oPB5XEcWJkrYqO_6BX-DLWPMR3HnZpi2ULthY8Sh37OQe33tmfB8IPaWRVInOzFVS71ZFKg7LTMmwLESZ17QWiTRFXN_nu7vFdMrGg8FPnwtzfJA3TXFywhb_VdUwBsrWqbOXUHc7KQzAZ1A6HEHtcPwnxX8YZyTwMQxxQClL9LJ_rLsFA0EGbhl8mjXgvALhVKMjAHSNjkrtmyLUPt5jy2dNirZ8p3nXoL-l67zKttizzeXUVPazEjawTgQTMDS6XpKJWQxNFKju0eL2WRobf_7HNwOOJS-E7yVi77H_EuCV0KW6jK0abbSDSs7mvw-BPQSPbAZ32sHRQalWhjlPNoLR_hFYx6Xo74GQtIs4dGY7YuBNctvPurXrrGeYJ-7M-viJScA76z7sTsaknU7XykqfASPSqaZh3PlMHydwypW2AY5t7JyeiuupOEm5mYbHV9AazVNWDNHa6O329F1XJDox7QHby3cZZy-7e3pO0hfufs7nUj1-tHcT3XALGzyygLyFBqq5ja7tuNCNO-i7xiX-8fUb1ojcxD08YotH3OERn8HjJvZoxB0aMaAROzTi02jE5Rds0IjnNRbYoRH30Yg9GrFD41308fX23tab0LUICSUlJNb9EZlUTNW0SmIZFUymFSGSFpLkogAyKgoBZ1lcURVnSoDJAk6d1pmCVSUFqnoPDZt5o-4jzIq4KKuEwnqoSrKaiKSOaC4r4Oh1zZhaRxv-z-YLWwmG_1XN6yjzKuE-zRkcMwewXSSYnyeoVu7pW3HCV5RHVloLA23RoiBZtJKOQVtmfPFFH1z25z1E17tH8REaHi6P1GN0VR4fzlbLJw7avwA1euR1 |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=OP61+%E2%80%93+2294%3A+Pantotenate+kinase+associated+neurodegeneration%3A+Clinical+assessment+and+genetic+characterization+by+means+of+a+Spanish+multi-centre+research+network&rft.jtitle=European+journal+of+paediatric+neurology&rft.au=Darling%2C+A.&rft.au=Decio%2C+A.&rft.au=Serrano%2C+M.&rft.au=Albesa%2C+S.+Aguilera&rft.date=2015-05-01&rft.issn=1090-3798&rft.volume=19&rft.spage=S19&rft.epage=S20&rft_id=info:doi/10.1016%2FS1090-3798%2815%2930062-3&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_S1090_3798_15_30062_3 |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F10903798%2FS1090379815X00043%2Fcov150h.gif |